WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 29, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, today announced that it will present at the Canaccord
Genuity 34th Annual Growth Conference at the Intercontinental
Hotel in Boston on Wednesday, August 13, 2014. Management is scheduled
to present at 8:30 a.m. Eastern Time. A live audio webcast and replay of
the presentation will be available for 30 days following the
presentation at http://wsw.com/webcast/canaccord14/atrc.
AtriCure management is also scheduled to participate in the Barrington
Research 7th Annual Fall Investment Conference at the Four
Seasons Hotel in Chicago on September 4, 2014.
About AtriCure, Inc.
Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy Ablation System is the first and only surgical device approved
for the treatment of Persistent and Longstanding Persistent forms of
Afib in patients undergoing certain open concomitant procedures.
AtriCure’s AtriClip Left Atrial Appendage (LAA) exclusion device is the
most widely sold device worldwide that is indicated for the occlusion of
the LAA. The company believes cardiothoracic surgeons are adopting its
ablation and LAA management devices for the treatment of Afib and
reduction of Afib related complications such as stroke. Afib affects
more than 5.5 million people worldwide.
Source: AtriCure, Inc.
Andy Wade, 513-755-4564
and Chief Financial Officer